Eloxx Pharmaceuticals
950 Winter Street
Waltham
Massachusetts
02451
United States
Tel: 1-781-577-5300
Website: http://www.eloxxpharma.com/
Email: info@eloxxpharma.com
About Eloxx Pharmaceuticals
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 2,000 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx’s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA. with R&D operations in Rehovot, Israel.
YEAR FOUNDED: 2013
LEADERSHIP:
Chairman of the Board & CEO: Bob Ward
CMO: Dr. Pedro Huertas
CFO: Gregory Weaver
VP CMC: John van Duzer
Investor Relations: Barbara Ryan
VP Translational Science: Neal Sharpe
117 articles about Eloxx Pharmaceuticals
-
Eloxx Pharmaceuticals Secures Debt Facility of Up to $30 Million from Hercules Capital
10/5/2021
Eloxx Pharmaceuticals, Inc., announced that the company has entered into a debt facility of up to $30.0 million with Hercules Capital, Inc., a specialty financing lender for life science and technology companies.
-
Eloxx Pharmaceuticals Announces Fast Track Designation for ELX-02 for the Treatment of Cystic Fibrosis Patients with Nonsense Mutations
9/9/2021
Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ELX-02, a drug candidate intended to treat cystic fibrosis patients with nonsense mutations. ELX-02 is currently in Phase 2 clinical trials in CF patients affected by nonsense mutations in the CFTR (CF transmembrane conductance regulator) gene for whom there are no effective disease modifying therapies.
-
Eloxx Pharmaceuticals Appoints Chief Medical OfficerAli Hariri, M.D. to Lead Clinical Development Efforts for Company Pipeline
9/8/2021
Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced the appointment of Ali Hariri, M.D., as its Chief Medical Officer, overseeing clinical development efforts for the company’s promising pipeline of therapies to treat rare diseases.
-
Eloxx Pharmaceuticals Reports Second Quarter 2021 Financial and Operating Results and Provides Business Update
8/16/2021
Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today reported its financial results for the three months ended June 30, 2021, and provided a business update.
-
Eloxx Pharmaceuticals Provides Enrollment Update for Ongoing Phase 2 Clinical Studies for Cystic FibrosisData Readout for First Four Treatment Arms Expected in the Fourth Quarter of 2021
7/6/2021
Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) today provided an update on enrollment for the ongoing global Phase 2 clinical program for ELX-02 for the treatment of cystic fibrosis (CF) in patients with at least one G542X allele.
-
CF Foundation Funds Three New Research Awards to Advance its Path to a Cure Initiative
5/27/2021
New funding awards include up to $2.6M to Eloxx Pharmaceuticals to identify potential therapies for CF nonsense mutations
-
Eloxx Pharmaceuticals Announces Funding Award from Cystic Fibrosis Foundation for Development of Ribosome Modulating Agents
5/27/2021
Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that the Company has received an award of up to $2.6M from the Cystic Fibrosis Foundation.
-
Eloxx Pharmaceuticals, Inc. Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
5/18/2021
Eloxx Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the closing of an underwritten public offering of 38,333,334 shares of common stock at a public offering price of $1.35 per share.
-
Eloxx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
5/14/2021
Eloxx Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the pricing of an underwritten public offering of 33,333,334 shares of common stock at a public offering price of $1.35 per share
-
Eloxx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
5/13/2021
Eloxx Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it has commenced an underwritten public offering of shares of its common stock.
-
Cystic Fibrosis: One Patient’s Story, Current Treatments and Exciting New Therapies on the Horizon
5/11/2021
“The recent progress of cystic fibrosis drugs has been amazing and, in my case, miraculous,” said Kelly Peters, who lives with cystic fibrosis. “The new drugs are not a cure, but they feel pretty close.” -
Eloxx Pharmaceuticals Reports First Quarter 2021 Financial and Operating Results and Provides Business Update
5/6/2021
Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today reported its financial results for the three months ended March 31, 2021 and provided a business update.
-
Eloxx Pharmaceuticals Adds Additional Treatment Arm to Ongoing Phase 2 Clinical Studies for Cystic Fibrosis
4/29/2021
Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) today announced the addition of a new study arm in the ongoing global Phase 2 clinical program for ELX-02 for the treatment of cystic fibrosis (CF) in patients with at least one G542X allele.
-
Eloxx Pharmaceuticals Acquires Zikani Therapeutics
4/1/2021
Combined Company to be Leader in Ribosomal RNA-Targeted Genetic Therapy Bringing Together Complementary Platforms Maximizes Potential for ELX-02 for Cystic Fibrosis in Phase 2 Development Adds Preclinical Stage Pipeline in Rare Diseases and Oncology Targeting RNA and Ribosomal Mutations Expects to File IND for First Oral Drug to Treat Patients with R ecessive Dystrophic and Junctional Epidermolysis Bullosa (RDEB and JEB)
-
Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operating Results and Provides Business Update
3/11/2021
Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today reported its financial results for the three and twelve months ended December 31, 2020 and provided a business update.
-
Eloxx Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Business Update on March 11, 2021
3/4/2021
Company management to host a webcast and conference call to provide a business update and review financial results at 4:30 p.m. ET
-
Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Cystic FibrosisPublication titled: “Targeting G542X CFTR Nonsense Alleles With ELX-02 Restores CFTR Function in Human-Derived Intestinal Organoids”
2/9/2021
Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that a scientific manuscript titled: “ Targeting G542X CFTR Nonsense Alleles With ELX-02 Restores CFTR Function in Human-Derived Intestinal Organoids ” was p
-
Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Clinical Pharmacology in Drug Development
1/26/2021
Eloxx Pharmaceuticals announced a Publication titled: “ A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX-02 in Healthy Subjects”
-
Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Clinical Pharmacology
1/20/2021
Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that a scientific manuscript titled: “Phase 1 Renal Impairment Trial Results Enable Targeted Individualized Dosing of ELX-02 in Nephropathic Cystinosis Patients,”
-
Clinical Catch-Up: January 11-15
1/18/2021
The year is starting to pick up in terms of clinical trial announcements. Here’s a look at last week’s news.